U.S. markets closed

Sino Biopharmaceutical Limited (SMZ1.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.5096+0.0094 (+1.88%)
At close: 10:30AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5002
Bid0.5112 x 1111100
Ask0.5312 x 1111100
Day's Range0.5088 - 0.5096
52 Week Range0.4411 - 0.6496
Avg. Volume1,701
Market Cap4.102B
Beta (5Y Monthly)N/A
PE Ratio (TTM)15.44
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SMZ1.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      invoX Pharma and F-star Therapeutics issue Joint Statement

      LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States (“CFIUS”) about the terms of a mitigation agreement to add

    • Reuters

      China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

      China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. The decline from 2.06 billion yuan ($299.8 million) to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO's products, the firm said in a company filing published on Sunday. CanSinoBIO, which sells a one-dose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said half-year net profit dropped by 98.7% year-on-year.

    • Zacks

      F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

      Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.